2X Oncology - OV’s spinout - to Participate in Two Upcoming Investor Conferences

Hoersholm, Denmark October 31th  2017 – Oncology Venture Sweden AB (OV:ST) announces that its US spinout 2X Oncology, Inc. ("2X Oncology " or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in hard-to-treat cancers, will participate in the Life Sciences Summit 2017 on November 1-2 in New York City and the Jefferies 2017 London Healthcare Conference on November 15-16.

Chief Executive Officer George O. Elston will participate in and hold 1x1s with investors at both conferences, joined by Chief Financial Officer Jarne Elleholm.

Additionally, Mr. Elston will present in the Emerging Company Showcase at the Life Sciences Summit on Thursday, November 2, 2017 at 3:30pm EST, with a discussion period to follow.

Investors wishing to meet with 2X Oncology at or around either conference should notify the respective conference one-on-one desk, or contact Amy Raskopf to schedule a meeting.

About 2X Oncology

2X Oncology Inc. is a clinical stage precision medicine company developing targeted therapeutics addressing significant unmet needs in hard-to-treat cancers.  Our pipeline leverages a proprietary Drug Response Predictor (DRP®) technology generating drug specific companion diagnostics to identify patients who are most likely to respond and benefit from treatment.  DRP® also identifies likely non-responder patients, providing a precision medicine approach for the treatment of patients who can benefit from our therapies. 

The 2X Oncology pipeline of product candidates, including a PARPi, are focused on the treatment of breast, ovarian, prostate and pancreatic cancers and primary and secondary brain tumors.  These programs have demonstrated clinical efficacy and safety and are positioned to enter focused Phase 2 studies with study data and potential accelerated approval filings expected in 2H 2018.

A Cambridge, MA based spin-out from Oncology Venture ApS, 2X works in close collaboration with Oncology Venture and leverages a Danish registry of over 1,200 cancer patients for initial clinical studies. Learn more at 2xoncology.com.

Contact to 2X

Amy Raskopf

+1 917.673.5775



Twitter: @2xoncology

For further information, please contact:

Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
   or Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com 

About Oncology Venture Sweden AB 

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP™) technology in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP™ and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis® for breast cancer in collaboration with Cadila Pharmaceuticals; Irofulven developed from a fungus for prostate cancer; and APO010 – an immuno-oncology product for multiple myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US-based company focusing on precision medicine for women’s cancers with a pipeline of three promising Phase 2 product candidates, and Danish OV-SPV 2 which will test and potentially develop the Novartis small molecule kinase inhibitor. Oncology Venture currently owns 92% of 2X Oncology Inc. and 40% of OV-SPV2 ApS. 


Documents & Links